Tharimmune Inc (THAR)

Nov 13, 2025, 8:05 AM EST - 21 days ago

Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids

Nov 6, 2025, 4:16 PM EST - 4 weeks ago

Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy

Nov 3, 2025, 9:04 AM EST - 4 weeks ago

Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy

Sep 4, 2025, 8:01 AM EDT - 3 months ago

Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl

Sep 3, 2025, 7:30 AM EDT - 3 months ago

These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025

CGTX EQ IPDN MENS

Aug 20, 2025, 8:00 AM EDT - 3 months ago

Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments

Aug 13, 2025, 8:01 AM EDT - 4 months ago

Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl

Aug 5, 2025, 8:00 AM EDT - 4 months ago

Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors

Aug 4, 2025, 8:00 AM EDT - 4 months ago

Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery

Jul 23, 2025, 10:15 PM EDT - 4 months ago

Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

Jun 17, 2025, 8:01 AM EDT - 6 months ago

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

May 6, 2025, 8:01 AM EDT - 7 months ago

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

May 1, 2025, 8:01 AM EDT - 7 months ago

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

Apr 30, 2025, 8:01 AM EDT - 7 months ago

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

Apr 28, 2025, 8:01 AM EDT - 7 months ago

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

Apr 15, 2025, 9:00 AM EDT - 8 months ago

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

Apr 7, 2025, 8:00 AM EDT - 8 months ago

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

Mar 31, 2025, 8:00 AM EDT - 8 months ago

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

Mar 24, 2025, 8:00 AM EDT - 9 months ago

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

Mar 4, 2025, 7:00 AM EST - 9 months ago

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Jan 27, 2025, 8:30 AM EST - 11 months ago

Tharimmune to Present at the Microcap Conference 2025

Dec 16, 2024, 8:00 AM EST - 1 year ago

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Dec 6, 2024, 4:15 PM EST - 1 year ago

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Nov 18, 2024, 8:00 AM EST - 1 year ago

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Nov 13, 2024, 8:00 AM EST - 1 year ago

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Nov 4, 2024, 9:00 AM EST - 1 year ago

Tharimmune Announces Upcoming Conference Presentations

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Oct 28, 2024, 9:00 AM EDT - 1 year ago

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Jul 17, 2024, 8:30 AM EDT - 1 year ago

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Apr 30, 2024, 8:31 AM EDT - 1 year ago

Tharimmune To Participate in Two Upcoming Investor Conferences in May

Apr 23, 2024, 7:31 AM EDT - 1 year ago

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

Apr 15, 2024, 8:31 AM EDT - 1 year ago

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

OABI

Mar 5, 2024, 8:31 AM EST - 1 year ago

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Feb 20, 2024, 8:01 AM EST - 1 year ago

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Feb 5, 2024, 8:30 AM EST - 1 year ago

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Jan 29, 2024, 8:00 AM EST - 2 years ago

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

Dec 11, 2023, 8:01 AM EST - 2 years ago

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

Nov 30, 2023, 4:01 PM EST - 2 years ago

Tharimmune, Inc. Announces Closing of $11 Million Public Offering

Nov 27, 2023, 9:40 PM EST - 2 years ago

Tharimmune, Inc. Announces Pricing of $10 Million Public Offering

Nov 27, 2023, 8:00 AM EST - 2 years ago

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Nov 17, 2023, 7:00 AM EST - 2 years ago

Tharimmune Announces 1-for-25 Reverse Stock Split

Nov 6, 2023, 5:35 PM EST - 2 years ago

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis

Sep 22, 2023, 8:30 AM EDT - 2 years ago

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.

Sep 11, 2023, 11:51 AM EDT - 2 years ago

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Sep 8, 2023, 2:30 PM EDT - 2 years ago

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

Aug 9, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023